|Systematic (IUPAC) name|
|Molecular mass||477.549 g/mol (free base)|
A phase I study evaluated doses up to 80 mg, resulting in significant improvement in sleep latency without adverse effects.
In randomized, double-blind, placebo-controlled crossover trials, the 10 and 30 mg doses increased sleep time and reduced sleep latency. The subsequent study added a 60 mg dose and observed dose-dependent sleep promotion.
- Renzulli C, Nash M, Wright M, Thomas S, Zamuner S, Pellegatti M, Bettica P, Boyle G (February 2011). "Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans" (PDF). Drug Metab. Dispos. 39 (2): 215–27.
- "Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist.". Journal of Psychopharmacology 26: 1058–1070. Aug 2012.
- "Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia.". Neuropsychopharmacology 37: 1224–33. Apr 2012.
- "The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia.". Sleep 35: 1097–104. Aug 2012.
- Ratti E (December 13, 2007). "Psychiatry: An Innovative Drug Discovery Pipeline" (PDF) (GSK Neurosciences seminar). Archived from the original on December 5, 2008.
- Scammell TE, Winrow CJ (February 2011). "Orexin receptors: pharmacology and therapeutic opportunities". Annu. Rev. Pharmacol. Toxicol. 51: 243–66.